Patients diagnosed with leukemia approach their treatment with the hope of cure despite the effect on their quality of life. Some patients will be cured, others will die from treatment and some will die of their disease. A common theme at The New Directions in Leukemia Research (NDLR 2012) meeting was that cure will come if the drivers of the disease are better understood. Key messages were the power of combination platforms to understand the genetic and epigenetic modifications in leukemia to enable development of rational therapies, which can be tested via new clinical trial designs ensuring rapid clinical implementation.
therapy. He discussed the advancements that have enabled CML to change from an invariably fatal disease to a disease where the 5-year survival exceeds 85%. These include the development of a highly sensitive and quantitative test that monitors disease burden, a predictive test which examines patients intrinsic sensitivity to tyrosine kinase inhibitor therapy and an assay to determine the functionality of drug transporters, in particular OCT-1 (major active influx pump for Imatinib).
Importantly Tim Hughes and Deb White ( Adelaide, Australia) stressed that while tyrosine kinase inhibitor (TKI) therapy has improved the outlook for CML patients not all respond well, and that failure to respond is largely related to variability in the intrinsic sensitivity of patients to kinase inhibitors. This can now be assayed for at diagnosis. White demonstrated that understanding the underlying biology of individual patients could in turn provide previously unexplored insight into resistance mechanisms, paving the way for the development of combinational strategies to overcome primary resistance which may in turn reduce development of secondary resistance.
Hughes also discussed sustained disease control in some patients who had stopped taking imatinib.
His comments may link into an observation made by Jerry Radich (Fred Hutchinson Cancer Research
Center, Seattle, USA) that 20% of all individuals have constitutively activated IFNα genes, which might explain why 10-25% of CML patients respond to IFNα treatment and the fact that the response rate to IFNα is determined by the underlying activation status of the immune system. Collectively, these observations suggest a hitherto unexplored role for the immune system in drug-induced disease control and eradication.
Acute Myeloid Leukemia (AML) -present and future
Allan Burnett (School of Medicine, Cardiff University, Cardiff, UK) gave an overview of treatment in AML, highlighting the mammoth task of evaluating both currently used treatments, and strategies for evaluating emerging treatments. The use of large randomised trials in combination with cytogenetic and mutation status have seen the improvement of outcome for several groups of young AML patients. However, significant challenges posed are the heterogeneity of AML, the lack of treatments to improve the outcome of elderly patients and the inability of the current trial designs to test new compounds rapidly. Burnett outlined the 'pick a winner trial design' that enables the rapid and progressive incorporation of new compounds into the current low dose Ara-C standard of care treatment for elderly patients and allows for agents without promise to be quickly dropped (1) . For AML transformation by restoring quiescence and reducing DNA damage, suggesting that blocking apoptosis in MDS may lead to disease control.
HSC & LSC in the niche -time to leave home
LSC as the presumptive source of relapse in leukaemia, are masters of 'laying low' by maintaining quiescence and localising to sanctuary sites in the marrow, thereby evading therapy. The stromal cells of the marrow play an important role in facilitating this therapy resistance and therefore dissecting out the stem cell-stromal interaction in normal and neoplastic hematopoiesis is essential to target LSC as recently illustrated by the observation that disruption of the CXCR4/CXCL12 axis with CXCR4 antagonists sensitise LSC to conventional chemotherapy. Following and extending this logic, the application of a CXCR4 antagonist AMD3100 to mobilise HSC was examined by Linda Bendall (University of Sydney, Sydney, Australia) who described how the bioactive lipid, S1P, forms a gradient between tissue and blood directing lymphocyte trafficking. Using both pharmacological inhibition of S1P signalling and conditional mouse knockouts of the S1P receptor S1P1 and sphingosine kinase, Bendall and colleagues have shown that S1P is required for HSC egress from the marrow after mobilisation with CXCR4 antagonists (6) . As predicted by this model, the use of S1P agonist SEW2871 enhanced HSC mobilisation. The dual use of CXCR4 antagonists with S1P agonists may therefore be an efficient alternative to the use of G-CSF for stem cell mobilisation. 
